The Influence of Palliative Chemotherapy on the Quality of Life of Patients with Gastric Cancer

Česká verze

Authors: D. Šmíd ¹; T. Skalický ¹; J. Fichtl ¹; D. Kubačková ¹; J. Doležal ¹; P. Novák ¹; T. Svoboda ²; D. Slouka ³
Authors place of work: Chirurgická klinika LF UK a FN Plzeň ¹; Onkologická klinika LF UK a FN Plzeň ²; Otorhinolaryngologická klinika LF UK a FN Plzeň ³
Published in the journal: Klin Onkol 2016; 29(4): 279-286
Category: Původní práce
doi: https://doi.org/10.14735/amko2016279

Summary

Background:
Gastric cancer is a malignant disease with a poor prognosis. The incidence of gastric cancer in the Czech Republic in 2013 was 14.34 cases per 100,000 citizens. Unfortunately, most patients are diagnosed with advanced stage disease and therefore undergo palliative treatment. Some patients undergo surgery and a very small percentage undergo palliative chemotherapy. The five year survival rate for those with advanced gastric cancer ranges from 5–15%.

Methods:
This is a prospective study of patients undergoing chemotherapy for advanced gastric cancer. The aim was to assess the quality of life of those undergoing chemotherapy.

Results:
The results showed that chemotherapy reduced the quality of life for these patients.

Discussion:
Although palliative chemotherapy prolonged time to progression, it had little impact on overall survival. Conversely, chemotherapy reduced quality of life. Thus, clinicians and patients must decide whether to begin palliative chemotherapy. The final decision should be made by the patient after discussion with the treating clinician.

Conclusion:
Treatment of patients with gastric cancer must be undertaken on an individual basis. Those undergoing palliative treatment must play an active role in the decision process regarding chemotherapy and assess the potential benefits and drawbacks. Because chemotherapy treatment has a detrimental effect on quality of life, the decision should be based on factors that predict the likely therapeutic effect of chemotherapy. A definitive decision can then be made as to whether chemotherapy is indicated.

Key words:
gastric cancer – palliative chemotherapy – chemotherapy – quality of life – WHOQOL-BREF

This study was supported by grant of Internal Grant Agency of the Czech Ministry of Health No. NS14227-3.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
10. 1. 2016

Accepted:
8. 6. 2016

Zdroje

1. Svoboda T, Daum O, Šmíd D (eds). Management léčby karcinomu žaludku. Postrgrad Med 2014: 28– 31.

2. Šimša J (ed.). Karcinom žaludku. Praha: Maxdorf 2012.

3. Krška Z, Hoskovec D, Petruželka L. Chirurgická onkologie. Praha: Grada 2014.

4. Becker HD, Hohenberger W, Junginger T et al (eds). Chirurgická onkologie. 1. vyd. Praha: Grada 2005.

5. Min BH, Kang KJ, Lee JH et al. Endoscopic resection for undifferentiated early gastric cancer: focusing on histologic discrepancies between forceps biopsy-based and endoscopic resection specimen-based diagnosis. Dig Dis Sci 2014; 59(10): 2536– 2543. doi: 10.1007/ s10620-014-3196-1.

6. National Comprehensive Cancer Network [homepage on the Internet]. NCCN clinical practice guidelines in oncology, gastric cancer, version I.2014. Available from: www.nccn.org/ professionals/ physician_gls/ pdf/ gastric.pdf.

7. Slováček L, Slováčková B, Blažek M et al. Kvalita života onkologicky nemocných – definice, koncepce, možnosti hodnocení. Klin Onkol 2006; 19(3): 163– 166.

8. Žaloudík J. Karcinom žaludku a karcinom kolorekta: dva různé trendy v jedné trávicí trubici. Klin Onkol 2005; 18(1): 29–30.

9. Salajka F. Kvalita života onkologicky nemocných – kritérium úspěšnosti naší péče. Klin Onkol 2001; 14 (Zvláštní číslo): 27– 29.

10. Modrá kniha České onkologické společnosti. 20. aktualizace. Brno: Masarykův onkologický ústav 2015.

11. Smid D, Skalicky T, Dolezal J et al. Surgical treatment of gastric cancer. Bratisl Lek Listy 2015; 116(11): 666– 670.

12. DeVita VT, Lawrence TS, Rosenberg SA (eds). DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/ Lippincott Williams & Wilkins 2011.

13. Waddell T, Verheij M, Allum W et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diag-nosis, treatment and follow-up. Eur J Surg Oncol 2014; 40(5): 584– 591. doi: 10.1016/ j.ejso.2013.09.020.

14. Lee YJ, Suh SY, Choi YS et al. EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer. Support Care Cancer 2014; 22(7): 1941– 1948. doi: 10.1007/ s00520-014-2173-8.

15. Prigerson HG, Bao Y, Shah MA et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 2015; 1(6): 778– 784. doi: 10.1001/ jamaoncol.2015.2378.

16. Saikawa Y, Kubota T, Takahashi T et al. Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncol Rep 2005; 13(5): 865– 870.

17. Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014; 31(4): 906. doi: 10.1007/ s12032-014-0906-7.

18. Holubová E, Skřivanová K, Nedvěd J et al. Methods of assesing quality of life in women with breast cancer – overview and basic charakteristics. Klin Onkol 2015; 28(5): 332– 337.

19. Mayrbäurl B, Wintner LM, Giesinger JM et al. Chemotherapy line-associated differences in quality of life in patients with advanced cancer. Support Care Cancer 2012; 20(10): 2399– 2405. doi: 10.1007/ s00520-011-1355-x.

20. Farrell C, Brearley SG, Pilling M et al. The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer 2013; 21(1): 59– 66. doi: 10.1007/ s00520-012-1493-9.

21. Li S, Wang Y, Xin S et al. Changes in quality of life and anxiety of lung cancer patients underwent chemotherapy. Zhongguo Fei Ai Za Zhi 2012; 15(8): 465– 470. doi: 10.3779/ j.issn.1009-3419.2012.08.03.

22. Ock CY, Oh DY, Lee J et al. Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. Gastric Cancer 2016; 19(2): 597– 606. doi: 10.1007/ s10120-015-0481-4.

23. Petera J, Dvořák J, Melichar B et al. Chemoterapie v neoadjuvantní léčbě karcinomu žaludku. Klin Onkol 2002; 15(6): 216– 218.

24. Li X, Cai H, Zheng W et al. An individualized prognostic signature for gastric cancer patients treated with 5-fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget 2016; 7(8): 8743– 8755. doi: 10.18632/ oncotarget.7087.

25. Sasako M, Terashima M, Ichikawa W et al. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/ III gastric cancer. Gastric Cancer 2015; 18(3): 538– 548. doi: 10.1007/ s10120-014-0413-8.

26. Liu YP, Ling Y, Qi QF et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett 2013; 5(3): 935– 942.

27. Yang J, Zhou Y, Min K et al. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol 2014; 20(33): 11886– 11893. doi: 10.3748/ wjg.v20.i33.11886.

28. Shen XM, Zhou C, Lian L et al. Relationship between the DPD and TS mRNA expression and the response to S-1-based chemotherapy and prognosis in patients with advanced gastric cancer. Cell Biochem Biophys 2015; 71(3): 1653– 1661. doi: 10.1007/ s12013-014-0387-5.

29. Smid D, Kulda V, Srbecka K et al. Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int J Oncol 2016; 48(6): 2693– 2703. doi: 10.3892/ ijo.2016.3484.

30. Šmíd D, Kubačková D, Doležal J et al. Predictive and prognostic factors of gastric cancer. Rozhl Chir 2016; 95(4): 156– 161.

31. Kemmochi A, Inagawa S, Akashi Y et al. A case of advanced gastric cancer with a complete response to S-1 neoadjuvant chemotherapy in an elderly patient. Gan To Kagaku Ryoho 2016; 43(1): 115– 119.

32. Hasegawa K, Asakawa A, Kamiya A et al. A case of gastric cancer with adrenal metastasis that responded to chemotherapy. Gan To Kagaku Ryoho 2015; 42(12): 2078– 2080.

33. Teker F, Canbaz F, Kemal Y et al. A case of gastric cancer with liver metastases had a complete response with cisplatin and capecitabine as third-line chemotherapy. J Cancer Res Ther 2015; 11(4): 1026. doi: 10.4103/ 0973-1482.150348.

34. Katolická J, Rotnáglová S, Vaníček J. Kazuistika pacienta se značně pokročilým a diseminovaným karcinomem žaludku léčeným preparátem S-1. Klin Onkol 2014; 27(3): 207– 209. doi: 10.14735/ amko207.

35. Hess LM, Michael D, Mytelka DS et al. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer 2016; 19(2): 607– 615. doi: 10.1007/ s10120-015-0486-z.

36. National cancer institute, cancer statistics [homepage on the Internet]. Available from: http://seer.cancer.gov/statistics/summaries.html.